- Trials with a EudraCT protocol (367)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (49)
367 result(s) found for: Hepatocellular Carcinoma.
Displaying page 1 of 19.
EudraCT Number: 2006-002546-11 | Sponsor Protocol Number: HAN-HCC-002 | Start Date*: 2006-10-20 | |||||||||||
Sponsor Name:Medizinische Hochschule Hannover | |||||||||||||
Full Title: Offene Phase IIIb Studie zur Elimination von CD4+CD25+ regulatorischen T-Zellen bei Patienten mit fortgeschrittenem HCC durch die Gabe von Cyclophosphamid | |||||||||||||
Medical condition: Fortgeschrittenes Leberzellkarzinom | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002299-92 | Sponsor Protocol Number: 54/2008/U/Sper | Start Date*: 2008-06-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: METRONOMIC CAPECITABINE IN ADVANCED HEPATOCARCINOMA: A FASE II STUDY | |||||||||||||
Medical condition: Advanced Hepatocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000252-34 | Sponsor Protocol Number: CA2099DW | Start Date*: 2020-02-17 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma | ||||||||||||||||||
Medical condition: Hepatocellular Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005909-79 | Sponsor Protocol Number: PRIGA | Start Date*: 2012-04-12 | |||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | |||||||||||||
Full Title: Magnetic resonance with gadoxetic acid for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. Evaluation of its impact for the non-invasive diagnosis. | |||||||||||||
Medical condition: hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012570-13 | Sponsor Protocol Number: BAY73-4506/14596 | Start Date*: 2009-08-25 | |||||||||||
Sponsor Name:Bayer HealthCare AG, D51368 Leverkusen | |||||||||||||
Full Title: An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC) | |||||||||||||
Medical condition: Hepatocellular carcinoma, in patients who have failed (experienced radiological progression) previous treatment cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003151-38 | Sponsor Protocol Number: CA224-073 | Start Date*: 2020-12-14 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kin... | ||||||||||||||||||
Medical condition: Advanced Hepatocellular Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000963-41 | Sponsor Protocol Number: 104-06-301 | Start Date*: 2008-12-03 | |||||||||||
Sponsor Name:CELSION CORPORATION | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox (Thermally Sensitive Liposomal Doxorubicin) in Combination with Radiofrequency Ablation (R... | |||||||||||||
Medical condition: patients with Non-Resectable Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003114-12 | Sponsor Protocol Number: HBIG | Start Date*: 2022-11-04 | ||||||||||||||||
Sponsor Name:Medical University of Graz | ||||||||||||||||||
Full Title: Impact of Hepatitis B immunoglobulins in patients with chronic Hepatitis B on Hepatocellular Carcinoma – a proof of concept study | ||||||||||||||||||
Medical condition: Patients with both chronic hepatitis B and hepatocellular carcinoma. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002740-13 | Sponsor Protocol Number: CA209-459 | Start Date*: 2015-11-12 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) SE (Completed) FR (Completed) ES (Ongoing) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012576-27 | Sponsor Protocol Number: SORAMIC | Start Date*: 2010-04-09 | ||||||||||||||||||||||||||
Sponsor Name:Medical Faculty, University Magdeburg | ||||||||||||||||||||||||||||
Full Title: Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma | ||||||||||||||||||||||||||||
Medical condition: Patients with Hepatocellular carcinoma (liver-predominant disease) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Completed) PL (Completed) SI (Completed) IT (Completed) GB (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002767-98 | Sponsor Protocol Number: UCDCRC/19/01 | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC) | |||||||||||||
Medical condition: Patients with Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002053-30 | Sponsor Protocol Number: EMR200095-005 | Start Date*: 2014-05-16 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liv... | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003606-53 | Sponsor Protocol Number: CA224106 | Start Date*: 2022-06-14 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocell... | |||||||||||||
Medical condition: Advanced/metastatic hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006637-14 | Sponsor Protocol Number: A6181170 | Start Date*: 2008-09-01 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, 10017 | |||||||||||||
Full Title: A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SUNITINIB MALATE VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA | |||||||||||||
Medical condition: Advanced Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FR (Completed) DE (Prematurely Ended) BE (Completed) IT (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000232-34 | Sponsor Protocol Number: NASIR-HCC | Start Date*: 2017-09-11 | |||||||||||
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
Full Title: A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment o... | |||||||||||||
Medical condition: Hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002163-26 | Sponsor Protocol Number: PRI2017HUS7040 | Start Date*: 2018-07-03 | |||||||||||
Sponsor Name:Hôpitaux Universitaires de Strasbourg | |||||||||||||
Full Title: Pilot study on doxorubicin kinetic distribution during arterial chemoembolization | |||||||||||||
Medical condition: hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005422-76 | Sponsor Protocol Number: CRAD001C24100 | Start Date*: 2008-09-01 | |||||||||||
Sponsor Name:PD Dr. Gerhard Treiber | |||||||||||||
Full Title: Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An open label, stratified, single-arm phase II study of Bevacizumab and RAD001 | |||||||||||||
Medical condition: Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001770-40 | Sponsor Protocol Number: 11546 | Start Date*: 2005-06-03 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma. | |||||||||||||
Medical condition: advanced hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000234-42 | Sponsor Protocol Number: FAB0001 | Start Date*: 2022-05-27 | |||||||||||
Sponsor Name:Medical University of Vienna, Div. of Gastroenterology & Hepatology | |||||||||||||
Full Title: Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy – the FAB-HCC Trial | |||||||||||||
Medical condition: Hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004679-29 | Sponsor Protocol Number: P171001J | Start Date*: 2018-06-13 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial | |||||||||||||
Medical condition: Nivolumab in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
